| Today’s Big NewsMay 16, 2025 |
| By Nick Paul Taylor BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline. |
|
|
|
By Fraiser Kansteiner Under a mutual agreement with Novo Nordisk's board of directors, Lars Fruergaard Jørgensen is stepping down from the chief executive post he’s held for the past eight years. Novo didn’t mince words about the rationale behind the decision, pointing to “recent market challenges” and the precipitous decline of the company’s share price “since mid-2024.” |
By Gabrielle Masson Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to a well-tolerated safety profile and what analysts believe “sets a new bar” in terms of efficacy for the condition. |
Sponsored by Medrio Medrio CEO Nicole Latimer discusses strategiesthe company’s mission to streamline clinical trials, embrace meaningful innovation and support life sciences organizations from startup to FDA approval. |
|
Explore our end-to-end, integrated drug substance and drug product capabilities across biologic modalities. This presentation highlights recent expansions at the Stein, Switzerland site including the large-scale manufacturing expansion, dedicated to biologics filling in vials as liquid/lyo, PFS and cartridges, as well as ADC manufacturing services.
|
|
By James Waldron Eli Lilly is further expanding its RNA medicine strategy by tapping up South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. |
By James Waldron Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn that its financial future remains in doubt. |
By Darren Incorvaia,Zoey Becker After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new chief medical officer and R&D head of Syndax Pharmaceuticals. Botwood spent the last decade at BMS, most recently serving as head of worldwide medical oncology, and, before that, he spent 11 years as an oncology development leader at AstraZeneca. |
By Darren Incorvaia An infant named KJ has made history as the first patient to be treated with an in vivo CRISPR gene editing therapy designed specifically for him. |
By Ayla Ellison,Eric Sagonowsky,Kevin Dunleavy,Angus Liu This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
By Angus Liu With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an initial snub from the agency. |
By Zoey Becker The sale allows WuXi Biologics to solely focus on its Singapore capacities while marking the first step in Terumo's global expansion. |
By Angus Liu Pfizer and RemeGen's HER2 ADC delivered positive phase 3 results in a bladder cancer trial in China. Roche plans to invest nearly $300 million to build a new Chinese plant to produce Vabysmo. China's Hengrui Pharma is looking to raise up to $1.27 billion in its Hong Kong IPO. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
